$0.6954
At close: Mar 25, 7:34 PM EDT
$0.7377
0.046.08%
After Hours: 7:34 PM EDT
Comments
Loading...
Prelude Therapeutics Insider Trading Activity | NASDAQ:PRLD | Benzinga
Track the latest Prelude Therapeutics insider trading activity. Stay informed on recent buys, sells, and market impact for Prelude Therapeutics stock.
What is Insider Activity?
Insider trading activity involves company insiders, such as executives, directors, and employees, engaging in transactions of their own company's stock. Insiders' buy and sell transactions provide valuable insights into their confidence in the company's future performance.
What are Prelude Therapeutics Inc Insiders Doing?
At Prelude Therapeutics Inc, recent insider activity has drawn attention. Over the last 30 days, insiders have report no sales in the last 30 days, meanwhile, insiders have reported buying a total of 157.02K shares for a total value of $113.93K.
Notable Recent Insider Buys and Sales
- On March 14, 2025, Krishna Vaddi, the company's CEO purchased 97.5K shares for $0.71 each.
- On March 18, 2025, Krishna Vaddi, the company's CEO purchased 39.1K shares for $0.75 each.
- On March 24, 2025, Krishna Vaddi, the company's CEO purchased 20.42K shares for $0.73 each.
Ownership Statistics for Prelude Therapeutics Inc
Shares Outstanding
55.155M
Insider Shares Owned
2.371M
Insider Percentage Owned
4.31%
Institutional Shares Held
4.770M
Institutional Percentage Held
8.65%
| Mar 24, 2025 | Krishna Vaddi | CEO | 20.42K | $0.73 | $14.91K | BUY | 1.41% | 1.47M | Mar 20 - Mar 21 | View |
| Mar 18, 2025 | Krishna Vaddi | CEO | 39.10K | $0.75 | $29.46K | BUY | 2.78% | 1.45M | Mar 14 - Mar 17 | View |
| Mar 14, 2025 | Krishna Vaddi | CEO | 97.50K | $0.71 | $69.56K | BUY | 7.44% | 1.41M | Mar 12 - Mar 13 | View |
| Jan 03, 2025 | Krishna Vaddi | CEO | 5.00K | $1.21 | $6.04K | BUY | 0.89% | 566.21K | Dec 31 | View |
| Jan 02, 2025 | Krishna Vaddi | CEO | 10.00K | $1.20 | $12.00K | BUY | 1.81% | 561.22K | Dec 30 | View |
| Dec 26, 2024 | Andrew Combs | CHIEF CHEMISTRY OFFICER | 63.08K | $1.36 | $85.54K | BUY | 20.05% | 377.62K | Dec 20 - Dec 23 | View |
| Dec 20, 2024 | Bryant D. Lim | CLO, INTERIM CFO, CORP SEC. | 25.00K | $0.91 | $22.64K | BUY | 1041.67% | 27.40K | Dec 19 | View |
| Dec 20, 2024 | Krishna Vaddi | CEO | 106.89K | $0.93 | $99.33K | BUY | 24.06% | 551.22K | Dec 18 - Dec 19 | View |
| May 26, 2023 | Krishna Vaddi | CEO | 1.90K | $5.15 | $9.79K | BUY | 0.16% | 1.19M | May 24 - May 25 | View |
| May 25, 2023 | Bryant D. Lim | CHIEF LEGAL OFFICER, CORP SEC. | 2.40K | $5.39 | $12.94K | BUY | ∞ | 2.40K | May 24 | View |
| May 25, 2023 | Laurent Chardonnet | CHIEF FINANCIAL OFFICER | 5.00K | $5.50 | $27.50K | BUY | 13.45% | 42.16K | May 23 | View |
| May 25, 2023 | Krishna Vaddi | CEO | 11.86K | $5.63 | $66.75K | BUY | 1.01% | 1.19M | May 23 | View |
| May 24, 2023 | ORBIMED ADVISORS LLCOrbiMed Capital GP VI LLCORBIMED CAPITAL LLC | DIRECTOR | 869.57K | $5.75 | $5.00M | BUY | 8.89% | 10.65M | May 22 | View |
| May 24, 2023 | David P Bonita | DIRECTOR | 869.57K | $5.75 | $5.00M | BUY | 8.89% | 10.65M | May 22 | View |
| Apr 06, 2023 | Jane Huang | PRESIDENT, CMO | 24.22K | $6.12 | -$81.27K | SELL-OPTIONS | ∞ | 24.22K | Apr 04 - Apr 06 | View |
| Dec 21, 2022 | Krishna Vaddi | CEO | 19.19K | $5.13 | $98.45K | BUY | 3.65% | 544.32K | Dec 20 | View |
| Dec 12, 2022 | Laurent Chardonnet | CHIEF FINANCIAL OFFICER | 10.00K | $4.76 | $47.60K | BUY | 38.65% | 35.87K | Dec 08 | View |
| Jun 01, 2022 | Laurent Chardonnet | CHIEF FINANCIAL OFFICER | 10.00K | $4.23 | $42.30K | BUY | 68.97% | 24.50K | Jun 01 | View |
| Dec 17, 2021 | Deborah Morosini | EVP, CHIEF CLINICAL AFFAIRS | 0.00 | $12.35 | -$37.37K | SELL-OPTIONS | 0.00% | 444.00 | Dec 15 | View |
| Dec 15, 2021 | Andrew Combs | EVP, HEAD CHEMISTRY | 8.00K | $11.86 | $94.88K | BUY | 3.07% | 268.38K | Dec 13 - Dec 14 | View |
| Nov 18, 2021 | Deborah Morosini | EVP, CHIEF CLINICAL AFFAIRS | 0.00 | $14.36 | -$87.08K | SELL-OPTIONS | 0.00% | 444.00 | Nov 16 | View |
| Oct 06, 2021 | David Mauro | CHIEF MEDICAL OFFICER | 0.00 | $16.42 | -$436.00K | SELL-OPTIONS | 0.00% | 0.00 | Oct 05 | View |
| Sep 09, 2021 | David Mauro | CHIEF MEDICAL OFFICER | 0.00 | $19.29 | -$521.93K | SELL-OPTIONS | 0.00% | 0.00 | Sep 07 | View |
| Sep 07, 2021 | Christopher Pierce | EVP AND CHIEF BUSINESS OPER | 0.00 | $27.26 | -$490.04K | SELL-OPTIONS | 0.00% | 3.75K | Sep 02 | View |
| Aug 30, 2021 | Peggy Scherle | CHIEF SCIENTIFIC OFFICER | 0.00 | $18.59 | -$264.76K | SELL-OPTIONS | 0.00% | 172.92K | Aug 26 - Aug 27 | View |
| Aug 27, 2021 | Brian Piper | CHIEF FINANCIAL OFFICER | 0.00 | $17.62 | -$262.08K | SELL-OPTIONS | 0.00% | 0.00 | Aug 25 | View |
| Aug 17, 2021 | Peggy Scherle | CHIEF SCIENTIFIC OFFICER | 0.00 | $18.30 | -$76.64K | SELL-OPTIONS | 0.00% | 172.92K | Aug 13 | View |
| Aug 09, 2021 | David Mauro | CHIEF MEDICAL OFFICER | 0.00 | $16.49 | -$438.04K | SELL-OPTIONS | 0.00% | 0.00 | Aug 05 | View |
| Jul 29, 2021 | Peggy Scherle | CHIEF SCIENTIFIC OFFICER | 0.00 | $18.45 | -$680.78K | SELL-OPTIONS | 0.00% | 172.92K | Jul 27 | View |
| Jul 08, 2021 | David Mauro | CHIEF MEDICAL OFFICER | 0.00 | $14.68 | -$383.76K | SELL-OPTIONS | 0.00% | 0.00 | Jul 06 | View |
| Jun 09, 2021 | David Mauro | CHIEF MEDICAL OFFICER | 0.00 | $17.17 | -$458.27K | SELL-OPTIONS | 0.00% | 0.00 | Jun 07 | View |
| May 27, 2021 | Brian Piper | CHIEF FINANCIAL OFFICER | 0.00 | $18.08 | -$269.79K | SELL-OPTIONS | 0.00% | 0.00 | May 25 | View |
| May 11, 2021 | Peggy Scherle | CHIEF SCIENTIFIC OFFICER | 0.00 | $21.12 | -$393.89K | SELL-OPTIONS | 0.00% | 172.92K | May 07 | View |
| May 10, 2021 | David Mauro | CHIEF MEDICAL OFFICER | 0.00 | $21.01 | -$573.74K | SELL-OPTIONS | 0.00% | 0.00 | May 05 | View |
| Apr 30, 2021 | Christopher Pierce | EVP AND CHIEF BUSINESS OPER | 0.00 | $21.09 | -$126.54K | SELL-OPTIONS | 0.00% | 3.75K | Apr 29 | View |
| Apr 30, 2021 | Deborah Morosini | EVP, CHIEF CLINICAL AFFAIRS | 0.00 | $21.09 | -$123.76K | SELL-OPTIONS | 0.00% | 444.00 | Apr 29 | View |
| Apr 29, 2021 | David Mauro | CHIEF MEDICAL OFFICER | 0.00 | $18.64 | -$837.60K | SELL-OPTIONS | 0.00% | 0.00 | Apr 27 | View |
| Apr 21, 2021 | David Mauro | CHIEF MEDICAL OFFICER | 0.00 | $16.39 | -$725.10K | SELL-OPTIONS | 0.00% | 0.00 | Apr 19 | View |
| Apr 15, 2021 | Peggy Scherle | CHIEF SCIENTIFIC OFFICER | 0.00 | $19.88 | -$170.88K | GRANT | 0.00% | 172.92K | Apr 08 | View |
| Apr 15, 2021 | Christopher Pierce | EVP AND CHIEF BUSINESS OPER | 0.00 | $20.95 | -$7.62K | GRANT | 0.00% | 3.75K | Apr 08 | View |
| Apr 15, 2021 | Deborah Morosini | EVP, CHIEF CLINICAL AFFAIRS | 0.00 | $20.95 | -$3.81K | SELL-OPTIONS | 0.00% | 444.00 | Apr 08 | View |
| Apr 15, 2021 | David Mauro | CHIEF MEDICAL OFFICER | 0.00 | $20.12 | -$350.68K | SELL-OPTIONS | 0.00% | 0.00 | Apr 08 | View |
| Apr 09, 2021 | Peggy Scherle | CHIEF SCIENTIFIC OFFICER | 0.00 | $20.37 | -$582.17K | GRANT | 0.00% | 172.92K | Apr 07 | View |
| Apr 09, 2021 | Christopher Pierce | EVP AND CHIEF BUSINESS OPER | 0.00 | $20.99 | -$31.62K | GRANT | 0.00% | 3.75K | Apr 07 | View |
| Apr 09, 2021 | Deborah Morosini | EVP, CHIEF CLINICAL AFFAIRS | 0.00 | $20.97 | -$38.15K | SELL-OPTIONS | 0.00% | 444.00 | Apr 07 | View |
| Apr 09, 2021 | David Mauro | CHIEF MEDICAL OFFICER | 0.00 | $20.61 | -$575.95K | SELL-OPTIONS | 0.00% | 0.00 | Apr 07 | View |
| Sep 30, 2020 | David P Bonita | — | 9.57M | $19.00 | $23.50M | DERIVATIVE CONVERSION | ∞ | 9.25M | Sep 25 - Sep 29 | View |
| Sep 30, 2020 | BAKER BROS ADVISORS LP LPBaker Bros Advisors GP LLCBaker Brothers Life Sciences LPFELIX BAKERJULIAN BAKER | — | 9.91M | $19.00 | $30.00M | DERIVATIVE CONVERSION | ∞ | 9.25M | Sep 29 | View |
| Sep 29, 2020 | Andrew Combs | — | 1.00K | $19.00 | $19.00K | PURCHASE | 0.39% | 260.38K | Sep 29 | View |
| Sep 29, 2020 | ORBIMED ADVISORS LLCOrbiMed Capital GP VI LLCORBIMED CAPITAL LLC | — | 9.57M | $19.00 | $23.50M | DERIVATIVE CONVERSION | ∞ | 9.25M | Sep 25 - Sep 29 | View |
| Sep 29, 2020 | Mardi Dier | — | 10.00K | $19.00 | $190.00K | PURCHASE | ∞ | 10.00K | Sep 29 | View |
| Sep 29, 2020 | Deborah Morosini | — | 444.00 | $19.00 | $8.44K | PURCHASE | ∞ | 444.00 | Sep 29 | View |
| Sep 29, 2020 | Christopher Pierce | — | 3.75K | $19.00 | $71.25K | PURCHASE | ∞ | 3.75K | Sep 29 | View |
FAQ
Is insider trading legal?
Insider trading is legal so long as the insiders report those trades to the SEC. Illegal securities trading occurs when the insider is violating a fiduciary duty or fails to report their trades.
What are some examples of market manipulation?
Insider trading, pump and dump schemes, front running and wash trades are all examples of market manipulation. Investors who track insider asset movement should think carefully about why these insiders are trading their stocks before moving forward.
Browse insider trades on all stocks.